Publicaciones en colaboración con investigadores/as de University of Toronto (15)

2024

  1. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment

    Archivos de Bronconeumologia, Vol. 60, pp. S67-S76

2023

  1. Neurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation: a systematic review and meta-analysis

    World Journal of Pediatrics, Vol. 19, Núm. 8, pp. 727-740

  2. Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis

    Frontiers in Immunology, Vol. 14

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  2. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  3. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2021

  1. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  2. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  3. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

2019

  1. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 862-876

2018

  1. Early-drug development in the era of immuno-oncology: Are we ready to face the challenges?

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1727-1740

2017

  1. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

    International Journal of Gynecological Cancer, Vol. 27, Núm. 1, pp. 50-58

2013

  1. Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2

    Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8

2012

  1. Ovarian low-grade serous carcinoma: A comprehensive update

    Gynecologic Oncology, Vol. 126, Núm. 2, pp. 279-285

2011

  1. p16 INK4a expression and breast cancer risk in women with atypical hyperplasia

    Cancer Prevention Research, Vol. 4, Núm. 12, pp. 1953-1960